Lv2
160 积分 2024-03-13 加入
Osimertinib dose-reduction issues in EGFR-mutated metastatic NSCLC
1个月前
已关闭
Response to “Osimertinib dose-reduction issues in EGFR-mutated metastatic NSCLC”
1个月前
已关闭
Efficacy and safety of immune checkpoint inhibitors for individuals with advanced EGFR-mutated non-small-cell lung cancer who progressed on EGFR tyrosine-kinase inhibitors: a systematic review, meta-analysis, and network meta-analysis
1个月前
已完结
Characteristics of Epidermal Growth Factor Receptor-Mutant Nonsmall-Cell Lung Cancer Patients Benefiting From Immune Checkpoint Inhibitors: A Systematic Review and Meta-Analysis
1个月前
已完结
Consolidation thoracic radiotherapy after chemoimmunotherapy provides survival benefit in elderly patients with extensive-stage small-cell lung cancer: a multicenter study
4个月前
已完结
PhALLCON Soars to New Heights—Faster, Stronger, but Better?
6个月前
已完结
Clinical implications of PD ‐ L1 expression in oncogene‐driven NSCLC : Differential responses to targeted agents and immune checkpoint inhibitors
6个月前
已关闭
Therapy for Stage IV Non–Small Cell Lung Cancer With Driver Alterations: ASCO Living Guideline, 2026.3.0
7个月前
已完结
Therapy for Stage IV Non–Small-Cell Lung Cancer With Driver Alterations: ASCO Living Guideline
8个月前
已完结
Analysis of patients with locally advanced rectal cancer given neoadjuvant radiochemotherapy with or without RT dose intensification: A multicenter retrospective study – ATLANTIS part I
8个月前
已完结
皖公网安备34019202002308
